Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular dysplasia. Mutations in either ENG or ACVRL1 account for around 85% of cases, and 10% are large deletions and duplications. Here we present a large novel deletion in ACVRL1 gene and its molecular characterization in a 3 generation Italian family. We employed short tandem repeats (STRs) analysis, direct sequencing, multiplex ligation-dependant probe amplification (MLPA) analysis, and ‘deletion-specific' PCR methods. STRs Analysis at ENG and ACVRL1 loci suggested a positive linkage for ACVRL1. Direct sequencing of this gene did not identify any mutations, while MLPA identified a large deletion. These results were confirmed and exactly characterized with a ‘deletion-specific' PCR: the deletion size is 4,594 bp and breakpoints in exon 3 and intron 8 show the presence of short direct repeats of 7 bp [GCCCCAC]. We hypothesize, as causative molecular mechanism, the replication slippage model. Understanding the fine mechanisms associated with genomic rearrangements may indicate the nonrandomness of these events, highlighting hot spots regions. The complete concordance among MLPA, STRs analysis and ‘deletion-specific PCR' supports the usefulness of MLPA in HHT molecular analysis.

Keywords:
ACVRL1, Large deletion, MLPA, Short direct repeats, Slippage
1.
Abeysinghe SS, Chuzhanova N, Krawczak M, Ball EV, Cooper DN: Translocation and gross deletion breakpoints in human inherited disease and cancer I: nucleotide composition and recombination-associated motifs. Hum Mutat 22:229-244 (2003).
2.
Bacolla A, Wojciechowska M, Kosmider B, Larson JE, Wells RD: The involvement of non-B DNA structures in gross chromosomal rearrangements. DNA Repair (Amst) 5:1161-1170 (2006).
3.
Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, et al: A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 140:2155-2162 (2006).
4.
Chen JM, Chuzhanova N, Stenson PD, Ferec C, Cooper DN: Complex gene rearrangements caused by serial replication slippage. Hum Mutat 26:125-134 (2005a).
5.
Chen JM, Chuzhanova N, Stenson PD, Ferec C, Cooper DN: Meta-analysis of gross insertions causing human genetic disease: novel mutational mechanisms and the role of replication slippage. Hum Mutat 25:207-221 (2005b).
6.
Cole SG, Begbie ME, Wallace GM, Shovlin CL: A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42:577-582 (2005).
7.
David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S: Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109:1953-1961 (2007).
8.
Demura M, Takeda Y, Yoneda T, Furukawa K, Usukura M, et al: Two novel types of contiguous gene deletion of the AVPR2 and -ARHGAP4 genes in unrelated Japanese kindreds with nephrogenic diabetes insipidus. Hum Mutat 19:23-29 (2002).
9.
Eyries M, Coulet F, Girerd B, Montani D, Humbert M, Lacombe P, et al: ACVRL1 germinal mosaic with two mutant alleles in hereditary hemorrhagic telangiectasia associated with pulmonary arterial hypertension. Clin Genet 82:173-179 (2012).
10.
Faughnan ME, Palda VA, Garcia-Tsao G, Geist-hoff UW, McDonald J, et al: International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 48:73-87 (2011).
11.
Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, et al: A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4(SMAD4). Lancet 363:852-859 (2004).
12.
Govani FS, Shovlin CL: Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 17:860-871 (2009).
13.
Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, et al: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189-195 (1996).
14.
Ketterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS: The rates and patterns of deletions in the human factor IX gene. Am J Hum Genet 54:201-213 (1994).
15.
Lesca G, Burnichon N, Raux G, Tosi M, Pinson S, et al: Distribution of ENG and ACVRL1(ALK1) mutations in French HHT patients. Hum Mutat 27:598 (2006).
16.
Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, et al: Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 9:14-22 (2007).
17.
Lesca G, Genin E, Blachier C, Olivieri C, Coulet F, et al: Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients. Eur J Hum Genet 16:742-749 (2008).
18.
McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, et al: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345-351 (1994).
19.
McDonald J, Damjanovich K, Millson A, Wooderchak W, Chibuk JM, et al: Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis. Clin Genet 79:335-344 (2011).
20.
Olivieri C, Pagella F, Semino L, Lanzarini L, Valacca C, et al: Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies. J Hum Ge-net 52:820-829 (2007).
21.
Paracchini V, Seia M, Coviello D, Porcaro L, Costantino L, et al: Molecular and clinical features associated with CFTR gene rearrangements in Italian population: identification of a new duplication and recurrent deletions. Clin Genet 73:346-352 (2008).
22.
Prigoda NL, Savas S, Abdalla SA, Piovesan B, Rushlow D, et al: Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations. J Med Genet 43:722-728 (2006).
23.
Resta N, Giorda R, Bagnulo R, Beri S, Della Mina E, et al: Breakpoint determination of 15 large deletions in Peutz-Jeghers subjects. Hum Genet 128:373-382 (2010).
24.
Richards-Yutz J, Grant K, Chao EC, Walther SE, Ganguly A: Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. Hum Genet 128:61-77 (2010).
25.
Shoukier M, Teske U, Weise A, Engel W, Argy-riou L: Characterization of five novel large deletions causing hereditary haemorrhagic telangiectasia. Clin Genet 73:320-330 (2008).
26.
Shovlin CL: Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24:203-219 (2010).
27.
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, et al: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91:66-67 (2000).
28.
Stankiewicz P, Lupski JR: Structural variation in the human genome and its role in disease. Annu Rev Med 61:437-455 (2010).
29.
Taulan M, Guittard C, Theze C, Claustres M, Georges M: A novel double deletion underscores the importance of characterizing end points of the CFTR large rearrangements. Eur J Hum Genet 17:1683-1687 (2009).
30.
Woodcock CL, Ghosh RP: Chromatin higher-order structure and dynamics. Cold Spring Harb Perspect Biol 2:a000596 (2010).
31.
Wooderchak-Donahue W, Vaughn C, Chou LS, Lewis T, Sumner K, et al: Verification of multiplex ligation-dependent probe amplification probes in the absence of positive samples. Genet Test Mol Biomarkers 15:793-799 (2011).
32.
Wooderchak W, Gedge F, McDonald M, Kraut-scheid P, Wang X, et al: Hereditary hemorrhagic telangiectasia: two distinct ENG deletions in one family. Clin Genet 78:484-489 (2010).
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.